ArticleEmerging infectious diseases2020
Novel Subclone of Carbapenem-Resistant Klebsiella pneumoniae Sequence Type 11 with Enhanced Virulence and Transmissibility, China.
Article in Emerging infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 1 synthesis or guideline pooled it, 217 citations in OpenAlex.
- Association of Klebsiella pneumoniae sequence type 11 but not other virulence factors with patient mortality: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Genomic analyses identify nosocomial transmission of ST23 carbapenem-resistant hypervirulentVirulence · 2026Article
- A fitness advantage from the pLVPK plasmid fuels the global spread of a carbapenem-resistant hypervirulent Klebsiella pneumoniae high-risk clone: ST11-KL64.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- GM000287 is a conserved determinant of serum resistance and virulence in Klebsiella pneumoniae.PLoS pathogens · 2026Article
- The Evolving Clonal, Plasmid-Mediated Resistome, Virulome and Therapeutic Landscape of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Genomic characterization of carbapenemase-producing Enterobacterales from wastewater reveals the convergence of KPC-2 and GES-16 in Brazil.Environmental monitoring and assessment · 2026Article
- Article
- Enhanced invasiveness promotes the dominance of a widely-distributed carbapenem-resistant virulence-plasmid-carrying Klebsiella pneumoniae sublineage.Nature communications · 2026Article
- Life Identification Numbers: A strain nomenclature approach to aid epidemiological surveillance of bacterial pathogens.PLoS biology · 2026Article
- Clinical outcomes and plasmid-associated features in KPC-producing Klebsiella pneumoniae bacteraemia.Tropical medicine and health · 2026Article
- Genetic clusteringof KPC-2-producing carbapenem-resistant Klebsiella pneumoniae ST5422-KL19 in Shanghai, China.BMC microbiology · 2026Article
- Human antibodies as emerging drugs for antimicrobial resistance.Trends in immunology · 2026Review
- Molecular analysis of polymyxin B resistance in clinical carbapenem-resistant Klebsiella pneumoniae isolates from a large tertiary care teaching hospital in Southwest China.BMC microbiology · 2026Article
- Wzc mutation enhances virulence in CRKP ST11-KL64 via complement-mediated lysis and lipopolysaccharide release.Microbiology spectrum · 2026Article
- WGS-based in silico analysis of clinically-associated Klebsiella pneumoniae genomes: insights into antimicrobial resistance, virulence determinants, and plasmid dynamics.Molecular genetics and genomics : MGG · 2026Article
- Aerobactin is a key driver of hypervirulent Klebsiella pneumoniae translocation and virulence.PLoS pathogens · 2026Article
- Comparative genomic, phenotypic, and clinical characterization of ST11-KL25 and ST11-KL64 hypervirulent carbapenem-resistantAntimicrobial agents and chemotherapy · 2026Article
- [Clinical and molecular characteristics of neonatalZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Cefiderocol resistance in a clinical ST11-KL64 hypervirulent Klebsiella pneumoniae isolate mediated by a novel CirA truncation and SHV-12 β-lactamase.BMC microbiology · 2026Article
- Clinical characteristics and molecular evolution of ST11-KL64 carbapenem-resistant hypervirulentMicrobiology spectrum · 2026Article
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to clarify the epidemiologic and clinical importance of evolutionary events that occurred in carbapenem-resistant Klebsiella pneumoniae (CRKP). We collected 203 CRKP causing bloodstream infections in a tertiary hospital in China during 2013-2017. We detected a subclonal shift in the dominant clone sequence type (ST) 11 CRKP in which the previously prevalent capsular loci (KL) 47 had been replaced by KL64 since 2016. Patients infected with ST11-KL64 CRKP had a significantly higher 30-day mortality rate than other CRKP-infected patients. Enhanced virulence was further evidenced by phenotypic tests. Phylogenetic reconstruction demonstrated that ST11-KL64 is derived from an ST11-KL47-like ancestor through recombination. We identified a pLVPK-like virulence plasmid carrying rmpA and peg-344 in ST11-KL64 exclusively from 2016 onward. The pLVPK-like-positive ST11-KL64 isolates exhibited enhanced environmental survival. Retrospective screening of a national collection identified ST11-KL64 in multiple regions. Targeted surveillance of this high-risk CRKP clone is urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.